Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.
作者信息
Tripodi Armando, Santoro Rita C, Testa Sophie, Molinari Angelo C, Bernardini Sergio, Golato Maria, Lippi Giuseppe, Ageno Walter, Santagostino Elena
机构信息
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Haemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
Centre for Haemorrhagic and Thrombotic Diseases, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy.
出版信息
Blood Transfus. 2019 May;17(3):229-236. doi: 10.2450/2019.0241-18. Epub 2019 Feb 4.
Abstract
摘要
相似文献
1
Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.关于血友病患者实验室检测的立场文件。SISET、AICE、SIBioC和SIPMeL的共识文件。
Blood Transfus. 2019 May;17(3):229-236. doi: 10.2450/2019.0241-18. Epub 2019 Feb 4.
2
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.无抑制剂的重型血友病 A 患者预防治疗的管理：AICE 建议，重点关注与 SIBioC、SIMEU、SIMEUP、SIPMeL 和 SISET 合作的急诊情况。
Haemophilia. 2020 Nov;26(6):937-945. doi: 10.1111/hae.14172. Epub 2020 Oct 23.
3
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.接受emicizumab 预防治疗的 A 型血友病伴抑制物患者的紧急管理：与 SIBioC、SIMEU、SIMEUP、SIPMeL 和 SISET 合作的 AICE 实践指南。
Blood Transfus. 2020 Mar;18(2):143-151. doi: 10.2450/2019.0186-19. Epub 2019 Oct 18.
4
Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.直接口服抗凝剂患者实验室检测立场文件。SISET、FCSA、SIBioC 和 SIPMeL 的共识文件。
Blood Transfus. 2018 Sep;16(5):462-470. doi: 10.2450/2017.0124-17. Epub 2017 Sep 13.
5
Unexpected haemophilia despite pre-natal testing - a combined haemophilia A and haemophilia B family.尽管进行了产前检测仍出现意外血友病——一个A型血友病和B型血友病合并的家族
Br J Haematol. 2017 Oct;179(2):182. doi: 10.1111/bjh.14840. Epub 2017 Jul 5.
6
[Diagnosis of hemophilia and Willebrand-Jürgens syndrome. 2. Results of studies in hemophilia patients and hemophilia carriers].[血友病和血管性血友病综合征的诊断。2. 血友病患者及血友病携带者的研究结果]
Z Gesamte Inn Med. 1985 Aug 15;40(16):479-83.
7
Haematology clinic: Haemophilia A.血液科门诊：甲型血友病。
Hematology. 2014 Apr;19(3):181-2. doi: 10.1179/1024533214Z.000000000262.
8
Expecting the unexpected: Acquired haemophilia A in a patient with homozygous factor V deficiency.意料之外的情况：一名纯合子因子V缺乏症患者发生获得性血友病A。
Haemophilia. 2019 Mar;25(2):e101-e103. doi: 10.1111/hae.13669. Epub 2019 Jan 28.
9
Women with haemophilia also exist.患血友病的女性也存在。
Lancet Haematol. 2021 Jan;8(1):e18. doi: 10.1016/S2352-3026(20)30409-9. Epub 2020 Dec 22.
10
The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.轻度甲型血友病的定义、诊断与管理：来自国际血栓与止血学会（ISTH）科学标准化委员会的交流文件
J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15.
引用本文的文献
1
Anesthetic considerations for joint replacement surgery in hemophilic arthropathy: a comprehensive review.血友病性关节病关节置换手术的麻醉考量：综述
Anesth Pain Med (Seoul). 2024 Jul;19(3):194-208. doi: 10.17085/apm.24047. Epub 2024 Jul 23.
2
Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.A型血友病患者紧急出血的管理：聚焦于艾美赛珠单抗的使用。
TH Open. 2024 Apr 17;8(2):e194-e201. doi: 10.1055/s-0044-1785525. eCollection 2024 Apr.
3
Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.优化和评估用于测量依库珠单抗血药浓度的两阶段显色测定法。
PLoS One. 2022 Jul 14;17(7):e0271330. doi: 10.1371/journal.pone.0271330. eCollection 2022.
4
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study.通过质谱法对甲型血友病患者血浆中的emicizumab进行定量分析：一项方法验证研究。
Res Pract Thromb Haemost. 2022 Jun 8;6(4):e12725. doi: 10.1002/rth2.12725. eCollection 2022 May.
5
Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A.专家意见：当前和未来预防疗法旨在提高血友病 A 患者的保护水平。
J Med Life. 2022 Apr;15(4):570-578. doi: 10.25122/jml-2022-0103.
6
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.重度甲型血友病无抑制物患者的当前治疗选择与管理：小型德尔菲共识
J Clin Med. 2022 Feb 2;11(3):801. doi: 10.3390/jcm11030801.
7
Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.血友病治疗的当前方法——罗马尼亚血液学会的共识观点
Ann Transl Med. 2021 Jul;9(13):1091. doi: 10.21037/atm-21-747.
8
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.接受emicizumab 预防治疗的 A 型血友病伴抑制物患者的紧急管理：与 SIBioC、SIMEU、SIMEUP、SIPMeL 和 SISET 合作的 AICE 实践指南。
Blood Transfus. 2020 Mar;18(2):143-151. doi: 10.2450/2019.0186-19. Epub 2019 Oct 18.
本文引用的文献
1
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.艾美赛珠单抗预防无抑制剂的血友病 A 患者出血。
N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.
2
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.利用抗独特型单克隆抗体在存在依库珠单抗的情况下常规检测因子 VIII 活性和抑制剂滴度。
J Thromb Haemost. 2018 Jul;16(7):1383-1390. doi: 10.1111/jth.14135. Epub 2018 May 27.
3
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.使用凝血酶生成试验对一名患有血友病且产生抑制剂并接受艾美赛珠单抗预防治疗的患者的突破性出血进行个性化治疗。
Haematologica. 2018 Apr;103(4):e181-e183. doi: 10.3324/haematol.2017.185330. Epub 2018 Feb 22.
4
International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.在临床止血实验室的血浆样本中评估 AFSTYLA 分析性能的国际比较现场研究。
J Thromb Haemost. 2018 Mar;16(3):555-564. doi: 10.1111/jth.13932. Epub 2018 Feb 1.
5
Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.选择一种基于单阶段激活部分凝血活酶时间的凝固检测法和两种显色检测法用于非活化因子 IX 聚乙二醇复合物（诺其）给药后监测的适用性评估。
J Thromb Haemost. 2017 Oct;15(10):1901-1912. doi: 10.1111/jth.13787. Epub 2017 Sep 11.
6
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.RNAi 治疗靶向血友病 A 或 B 的抗凝血酶。
N Engl J Med. 2017 Aug 31;377(9):819-828. doi: 10.1056/NEJMoa1616569. Epub 2017 Jul 10.
7
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
8
The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate.Afstyla单链FVIII浓缩物的凝血实验室监测。
Haemophilia. 2017 Sep;23(5):e469-e470. doi: 10.1111/hae.13290. Epub 2017 Jun 29.
9
Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.康西昔布，一种抗组织因子途径抑制剂抗体，通过血栓生成试验测量，可诱导血友病患者和健康受试者血浆中凝血酶生成增加。
Haemophilia. 2017 Sep;23(5):769-776. doi: 10.1111/hae.13260. Epub 2017 Jun 8.
10
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.新型延长半衰期FVIII/IX浓缩物的临床试验结果
J Clin Med. 2017 Mar 28;6(4):39. doi: 10.3390/jcm6040039.
Zotero 插件